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Background: Primary pancreatic leiomyosarcoma (PLMS) is rare. The clinical characteristics and prognosis is still
not completely understood. The aim of the present study is to identify the clinical characteristics and long-term
outcomes of PLMS from the existing reported cases in different scientific literature.
Methods: PLMS cases reported in Chinese and English journals were collected and reviewed. Clinical features and
long-term outcomes of these cases were summarized and analyzed statistically.
Results: A total of 69 cases reported from both Chinese and English journals were included in the present study.
An equal incidence in gender was observed. The mean age was 53.9 ± 14.7 years. The most common symptoms
were abdominal mass, abdominal pain, and weight loss. The mean size of the tumor was 11.4 ± 7.1 cm. The
incidence of PLMS between the head and body-tail of the pancreas had a similar pattern. Twenty-five percent of
patients had distant metastasis and 19% of patients had adjacent organs/vessels invasion at the time of diagnosis.
But lymph node metastasis was documented in only one (1.5%) patient. The median survival time was 48 months.
The overall 1-, 3-, 5-, and 10-year survival rates were 66.6%, 51.2%, 43.9%, and 29.3%, respectively. Results from the
multivariate analysis showed that non-radical resection (P = 0.000; hazard ratio (HR) 5.128; 95% confidence interval
(CI) 2.041-12.987) was the independent adverse prognostic factor. Adjacent organs/vessels invasion (yes) may be
considered as an another potential independent adverse prognostic factor (P = 0.071; HR 2.708; 95% CI 0.981-7.474).
Conclusions: PLMS is rare without specific clinical features. PLMS is an aggressive tumor and has a poor prognosis.
Radical resection can prolong survival time of the patients.
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Primary leiomyosarcoma is an extremely rare mesenchymal
tumor of the pancreas, which accounts for 0.1% of malig-
nant pancreatic tumors [1]. Primary pancreatic leiomyosar-
coma (PLMS) was first described by Ross in 1951 [2], and
to date 64 cases have been reported [3]. However, most of
them have been documented as single cases, with clinical
characteristics and prognosis which cannot be completely
understood. To understand the characteristics and long-
term outcomes of PLMS, the present study reviews earlier* Correspondence: zhao8028@263.net
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reproduction in any medium, provided the orreported cases in Chinese and English journals across the
globe.Methods
The systematic literature search was performed via
China Knowledge Resource Integrated (CNKI) database
to identify the cases reported in Chinese journals, with
the last search on 1 March 2013. A similar search was
made in MEDLINE, EMBASE, and the Cochrane data-
bases for cases reported in English journals. The primary
key words used were ‘pancreas and leiomyosarcoma’,
‘pancreatic and leiomyosarcoma’, ‘pancreas and mesen-
chymal tumor’, ‘pancreatic and mesenchymal tumor’,
‘pancreas and sarcoma’, and ‘pancreatic and sarcoma’.
Only the cases originated from the pancreas wereThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.













Male 33 ± 15.8 58.4 41.7
Female 98 ± 55.5 73.2 57.6
Age (years) 0.049
< 55 None 72.7 68.1
≥ 55 22 ± 7.9 59.1 27.9
Locations 0.477
Head 48 ± 26.5 70.8 58.8
Body-tail 33 ± 16.4 71.2 41.9
Size (cm) 0.092
< 10 33 ± 17.6 74.3 67.5
≥ 10 None 67.9 43.6
Gross morphology 0.142
Solid None 75.6 56.7
Cystic 12 ± 3.3 40 20
Mixed None 80 80
Distant metastasis 0.007
Yes 12 ± 6.3 50.0 0




Yes 6 ± 1.4 25.0 25.0
No 48 ± 29.4 82.8 56.6
Radical resection 0.000
Yes 98 ± 45.2 80.5 72.2
No 8 ± 3.5 40.3 0
Due to censored data ≥50%, the median survival time cannot be calculated.
A two-sided P value <0.05 was considered statistically significant.
SE, standard error.
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outcomes of these cases were summarized and analyzed.
SPSS v.13.0 (SPSS, Inc., Chicago, IL, USA) was used for
all analyses. The Pearson χ2 test and Fisher’s exact test
were used to compare categorical variables. The Kaplan-
Meier method was used to calculated overall survival (OS)
using the log-rank test. Cox regression analysis was
performed for multivariate survival analysis. A two-
sided P value <0.05 was considered statistically significant.
Results
Demographic and clinical data
Twenty cases were reported in Chinese journals (Additional
file 1), and 49 cases were reported in English journals
[1,2,4-35] (Additional file 2). A total of 69 cases were
included in the present study. The gender of 68
patients in these 69 cases was documented, which was
35 men and 33 women. An equal incidence in gender
was observed (male-female ratio of 1.06) in the data.
The mean age was 53.9 ± 14.7 years (median, 53 years;
range, 14-87 years).
Symptoms were described in 63 cases and of which 58
patients had symptoms. The most common symptoms
were abdominal mass (29 cases), abdominal pain (25
cases), and weight loss (19 cases). Other symptoms like
jaundice (8 cases), anemia (6 cases), gastrointestinal bleed-
ing (5 cases), and vomiting (5 cases) were also reported.
The tumor location was documented in 63 cases. The
tumors were located in the head of the pancreas in 30
cases, and in the body-tail in 32 cases. One case had
tumor in the whole pancreas. The mean size was 11.4 ±
7.1 cm (median, 10 cm; range, 1-30 cm). The gross
morphology was recorded in 49 cases. Twenty-six tu-
mors were solid mass, eight tumors were cystic mass,
and fifteen were mixed mass.
The status of metastasis and regional invasion at the
time of diagnosis were identified in 68 patients. Seven-
teen (25%) patients had distant metastasis and 13 (19%)
patients had adjacent organs/vessels invasion. Lymph
node metastasis was documented in only one (1.5%) pa-
tient. Men had a higher incidence of metastasis and re-
gional invasion than women (19/35 vs. 11/33; P = 0.082).
The surgical treatment method was illustrated in 62
cases, of which 40 cases achieved radical resection, and
22 cases underwent palliative resection or biopsy.
Survival analysis
Forty-nine cases with long-term outcomes data were in-
cluded in the survival analysis. The median survival time
was 48 months. The overall 1-, 3-, 5-, and 10-year sur-
vival rates were 66.6%, 51.2%, 43.9%, and 29.3%, respect-
ively. Univariate analysis showed that age ≥55 years,
distant metastasis (yes), adjacent organs/vessels invasion
(yes), and radical resection (no) were the potential adverseprognostic factors (Table 1). Multivariate analysis of the
cases showed that non-radical resection (P = 0.000; hazard
ratio (HR) 5.128; 95% confidence interval (CI) 2.041-
12.987) was the independent adverse prognostic factor.
Adjacent organs/vessels invasion (yes) might be also con-
sidered as another independent adverse prognostic factor
(P = 0.071; HR 2.708; 95% CI 0.981-7.474) (Table 2).
Discussion
PLMS is rare. Earlier studies by Baylor et al. showed
only five leiomyosarcomas among 5,057 pancreatic ma-
lignant tumors screened [1]. PLMS is considered to
originate either from the smooth muscle region of the
pancreatic ducts or the wall of small intra-pancreatic
vessels [4]. Leiomyosarcomas originating from the stom-
ach, duodenum, and retroperitoneal organs often invade
Table 2 Multivariate analysis of potential prognostic
factors







0.071 2.708 0.981 7.474
Radical resection (no) 0.000 5.128 2.041 12.987
A two-sided P value <0.05 was considered statistically significant.
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of PLMS is needed to rule out tumors originating from
these adjacent organs.
A generally equal incidence of PLMS in gender was
observed. There were 35 men and 33 women with a ra-
tio of 1.06. The age of the patients ranged from 14 to
87 years (median, 53 years). The most common symp-
toms observed in the patients were abdominal mass, ab-
dominal pain, and weight loss, but no specific symptoms
were recorded from any of the patients diagnosed with
PLMS. Small tumors usually had no symptoms and were
found incidentally [36]. The mean size of tumors was
11.4 ± 7.1 cm (range, 1-30 cm). Twenty-three of 49
tumors were mixed or cystic mass. Large tumors with
cystic degeneration presented a highly aggressive malig-
nancy, such as adjacent organ invasion and distant me-
tastasis [6]. The tumors were located in the head of the
pancreas in 30 cases and in the body-tail in 32 cases.
There was a similar incidence between the head and
body-tail.
Due to its presence as an obvious mass, the tumor can
be found easily by imaging studies. Trans-abdominal
ultrasonography (TAUS), computed tomography (CT),
positron emission tomography and computed tomog-
raphy (PET/CT), magnetic resonance imaging (MRI),
angiography, and endoscopic ultrasonography (EUS)
were all effective in diagnosing the PLMS, but there are
no specific imaging features [7]. PLMS appears as a
heterogeneous, hypervascular mass on CT scan. As the
tumor volume increases, hemorrhagic, necrotic, and cys-
tic changes can be observed [5,8]. Tumors with cystic le-
sions can be confused with pseudocysts of the pancreas
[6,9]. PLMS appears as a high incidence of distant me-
tastasis and regional invasion with rare lymphatic in-
volvement, which could be the key point to differential
diagnosis. It is difficult to do preoperative qualitative
diagnosis by non-invasive diagnostic method. CT or US
guided fine-needle aspiration biopsy (FNAB) is an alter-
native diagnostic method for PLMS. Three of four cases
showed a definite diagnosis through US-guided FNAB
reported in literature [3].
The accurate diagnosis of PLMS depends mainly on the
histological examinations and immunohistochemical stain-
ing. Histologically, PLMS showed well-formed fascicles ofspindle cells with blunt-ended nuclei intersecting at vertical
angles, varying degrees of pleomorphism, and a substantial
number of mitosis [10,11]. However, it is difficult to histo-
logically differentiate PLMS from inflammatory myofibro-
blastic tumors and non-myogenic spindle cell sarcomas,
namely fibrosarcomas, malignant fibrous histiocytomas,
and malignant peripheral nerve sheath tumors [10]. There-
fore, an immunohistochemical staining is crucial for an ac-
curate diagnosis. Immunohistochemical examinations have
an important value in evaluating spindle cell tumors which
were supposed to be of smooth muscle origin. These tu-
mors are positive for muscle markers (such as α-smooth
muscle actin, MSA, and desmin), with negative expression
of epithelial (such as cytokeratin, EMA, and CEA) and
neural (such as S100 protein) markers [10].
PLMS is an aggressive tumor. In the present system-
atic review, 25% of patients had distant metastasis and
19% of patients had adjacent organs/vessels invasion at
the time of diagnosis. Lymph node metastasis was not
common which was documented only in one patient
(1.5%). This feature helps us to differentiate PLMS from
other pancreatic malignant tumors and more surgeons
prefer to perform a local radical resection rather than
extensive node dissection based on this feature. Gender
may be related to the degree of malignancy. Men seem-
ingly had a higher incidence of metastasis and regional
invasion than women (P = 0.082).
Survival analysis showed that median survival time of
PLMS was 48 months. The overall 1-, 3-, 5-, and 10-
year survival rates were 66.6%, 51.2%, 43.9%, and 29.3%,
respectively. From univariate analysis, we showed that
age ≥55 years, distant metastasis (yes), adjacent organs/
vessels invasion (yes), and radical resection (no) were
the potential adverse prognostic factors of PLMS.
Multivariate analysis indicated that non-radical resec-
tion was the independent adverse prognostic factor.
Radical resection was associated with prolonged overall
survival time. Adjacent organs/vessels invasion (yes) might
be another independent adverse prognostic factor, but
statistical difference was not observed (P = 0.071). Al-
though the dimension of tumors is an important indicator
with regard to resectability, large tumor size was not an ef-
fective predictor of adverse prognosis in the current study.
Mitotic counts >10 mitoses per 10 high-powered fields
(HPFs) was reported as another adverse predictor [10].
Since data of this retrospective study extracted from the
literature were not in detail, a comprehensive prognosis
analysis could not be performed.
Conclusion
PLMS is a very rare malignant tumor of the pancreas.
Clinical features and imaging examinations are no spe-
cific. The accurate diagnosis of PLMS depends on histo-
logical examinations and immunohistochemical staining.
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